Cann Group Ltd. engages in the cultivation of medicinal cannabis and further processing into manufactured medicinal cannabis products. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-05-04. The principal activities of the Company include the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the group, the development and manufacture (via third party arrangements) of finished product formulations, and the pursuit and execution of various supply agreements with third parties. The company operates through cultivation of the medicinal cannabis segment. The firm supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. The company also owns Satipharm and its patent-protected capsule technology. The firm's research, cultivation, and good manufacturing practices (GMP) manufacturing facilities are in Melbourne, and a cultivation and GMP manufacturing facility is near Mildura, Victoria.
Follow-Up Questions
Who is the CEO of Cann Group Ltd?
Ms. Jenni Pilcher is the Chief Executive Officer of Cann Group Ltd, joining the firm since 2020.
What is the price performance of CNGGF stock?
The current price of CNGGF is $0.005, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Cann Group Ltd?
Cann Group Ltd belongs to Pharmaceuticals industry and the sector is Health Care
What is Cann Group Ltd market cap?
Cann Group Ltd's current market cap is $3.3M
Is Cann Group Ltd a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Cann Group Ltd, including 1 strong buy, 3 buy, 1 hold, 0 sell, and 1 strong sell
